| Literature DB >> 34326965 |
Bektas Murat1, Eylem Kivanc1, Rafet Dizman1, Gurbet Ozge Mert2, Selda Murat3.
Abstract
Introduction: Although the incidence of acute ST-segment elevation myocardial infarction (STEMI) in the elderly population has decreased in recent years, this is not the case for young people. At the same time, no reduction in hospitalization rate after STEMI was shown in young people. Clinical characteristics, risk factors, angiographic findings, in-hospital and one-year outcomes of patients under the age of 40 and their gender differences were investigated.Entities:
Keywords: Acute Myocardial Infarction; Coronary Angiography; Young Patients
Year: 2021 PMID: 34326965 PMCID: PMC8302902 DOI: 10.34172/jcvtr.2021.17
Source DB: PubMed Journal: J Cardiovasc Thorac Res ISSN: 2008-5117
Figure 1Baseline characteristics of female and male ST-segment elevation myocardial infarction patients ≤ 40 years old
|
|
|
|
|
| Age, median (Q1-Q3), years | 36 (33-38) | 36 (34-38) | 0.892 |
| Age group, n (%) | |||
| 18-30 years | 25 (14.2%) | 4 (11.1%) | 0.793 |
| 31-40 years | 151 (85.8%) | 32 (88.9%) | 0.354 |
| Risk factors of CAD, n (%) | |||
| Family history of CAD | 30 (17.2%) | 3 (8.3%) | 0.217 |
| Cigarette smoking | 107 (61.5%) | 19 (52.8%) | 0.354 |
| Alcohol abuse | 8 (4.6%) | 3 (8.3%) | 0.404 |
| Addiction to drugs | 2 (1.1%) | 0 (0.0%) | 1.000 |
| Hypertension | 26 (14.8%) | 6 (16.7%) | 0.799 |
| Diabetes mellitus | 25 (14.2%) | 5 (13.9%) | 1.000 |
| Obesity | 9 (5.1%) | 7 (19.4%) | 0.008 |
| Dyslipidemia | 56 (31.8%) | 10 (27.8%) | 0.697 |
| Renal insufficiency | 1 (0.6%) | 0 (0.0%) | 1.000 |
| Clinical Features | |||
| Typical chest pain, n (%) | 169 (96.0%) | 34 (94.4%) | 0.651 |
| Shortness of breath, n (%) | 26 (14.8%) | 13 (36.1%) | 0.008 |
| Out-of-hospital cardiac arrest, n (%) | 10 (5.7%) | 2 (5.6%) | 1.000 |
| Heart rate, median (Q1-Q3), bpm | 78(72-91) | 87(78-91) | 0.070 |
| Systolic blood pressure, median (Q1-Q3), mm Hg | 120(110-120) | 110(105-120) | 0.080 |
| Diastolic blood pressure, median (Q1-Q3), mm Hg | 70(65-77) | 70(60-71) | 0.414 |
| SpO2, median (Q1-Q3), % | 100(99-100) | 100(96-100) | 0.056 |
| Killip class on admission, n (%) | 0.019 | ||
| Class 1 | 155 (88.1%) | 26 (72.2%) | |
| Class 2 | 13 (7.4%) | 8 (22.2%) | |
| Class 3 | 5 (2.8%) | 0 (0.0%) | |
| Class 4 | 3 (1.7%) | 2 (5.6%) | |
| Type of myocardial infarction, n (%) | |||
| Anterior myocardial infarction | 97 (55.1%) | 27 (75.0%) | 0.027 |
| Anterolateral myocardial infarction | 7(4.0%) | 1 (2.8%) | 0.731 |
| Inferior myocardial infarction | 45 (25.6%) | 6 (16.7%) | 0.25 |
| Posterior myocardial infarction | 13 (7.4%) | 1 (2.8%) | 0.31 |
| Lateral myocardial infarction | 10 (5.7%) | 1 (2.8%) | 0.47 |
| Inferolateral myocardial infarction | 4(2.3%) | 0 (0.0%) | 0.36 |
| Laboratory results on admission, median (Q1-Q3) | |||
| Hemoglobin, g/dL | 15.6(14.6-16.6) | 14.7(13.0-15.8) | < 0.001 |
| Neutrophil, 10^3/µL | 7.04(5.25-10.43) | 7.49(5.31-9.86) | 0.890 |
| Glucose, mg/dL | 108(98-128) | 112(99-143) | 0.243 |
| Creatinine, mg/dL | 0.87(0.76-1.06) | 0.79(0.69-096) | 0.041 |
| Total cholesterol, g/L | 205(175-240) | 202(170-225) | 0.478 |
| LDL cholesterol, g/L | 123(99-151) | 131(104-145) | 0.821 |
| HDL cholesterol, g/L | 38.40(34.5-45.6) | 43.5(38-45.7) | 0.103 |
| Triglycerides,g/L | 162(111-263) | 124(98-180) | 0.114 |
| Hs-Trp, pg/mL | 170(36.1-360) | 302(66.5-4299.7) | 0.040 |
| CKMB, ng/mL | 6.9(1.55-17) | 17.8(3.15-68.16) | 0.028 |
Abbreviations: CAD, coronary artery disease; LDL, low-density lipoprotein; HDL, high-density lipoprotein; Hs-Trp, high sensitive troponin; CKMB, creatine kinase myocardial band
Coronary angiography findings and cardiac procedures
|
|
|
|
|
| Acute reperfusion therapy | 0.647 | ||
| IV fibrinolysis | 1 (0.6%) | 0 (0.0%) | |
| Primary PCI | 167 (95.4%) | 35(94.6%) | |
| Procedure access, n (%) | 0.069 | ||
| Radial access | 6 (3.4%) | 4 (11.1%) | |
| Femoral access | 170 (96.6%) | 32 (88.9%) | |
| Number of diseased vessels, n (%) | |||
| One vessel | 146(83.0%) | 29(80.6%) | 0.730 |
| Two vessels | 17(9.7%) | 4(11.1%) | 0.790 |
| Three vessels | 13(7.4%) | 3(8.3%) | 0.845 |
| Treated coronary arteries, n (%) | |||
| Left anterior descending artery | 99(56.3%) | 23(63.9%) | 0.390 |
| Circumflex artery | 18(10.2%) | 1(2.8%) | 0.150 |
| Right coronary artery | 25(14.2%) | 4(11.1%) | 0.620 |
| Left main artery | 1(0.6%) | 1(2.8%) | 0.210 |
| The others | 33(18.8%) | 7(19.4%) | 0.900 |
| Thrombus burden, n (%) | |||
| No thrombus | 125 (71.0%) | 26 (72.2%) | 0.885 |
| Moderate thrombus <2 diam. | 36(20.5%) | 7 (19.4%) | 0.89 |
| Large thrombus >2 diam. | 15(8.5%) | 3(8.3%) | 0.97 |
| Thrombus aspiration | 15 (8.6%) | 3 (8.3%) | 1.000 |
| Interventional therapy, n (%) | |||
| PTCA | 8 (4.6%) | 0 (0.0%) | 0.354 |
| BMS | 11 (6.9%) | 2 (5.7%) | 0.912 |
| DES | 140 (87.5%) | 32 (91.4%) | 0.854 |
| No stent implantation | 9 (5.6%) | 1 (2.9%) | 1.000 |
| CABG | 9 (5.2%) | 3 (8.3%) | 0.438 |
| Medication received within first 24 hrs. n (%) | |||
| Glycoprotein IIb/IIIa receptor antagonists | 49 (28.7%) | 12 (33.3%) | 0.554 |
| Aspirin | 168 (99.4%) | 36 (100.0%) | 1.000 |
| Statins | 168 (99.4%) | 33 (91.7%) | 1.000 |
| Beta-blockers | 82 (48.8%) | 17 (47.2%) | 1.000 |
| ACE inhibitors/angiotensin receptor II blockers | 66 (38.6%) | 16 (44.4%) | 0.575 |
| P2Y12 inhibitors | 163 (95.3%) | 35 (97.2%) | 1.000 |
| Low-molecular-weight heparin | 161 (93.6%) | 35 (97.2%) | 0.696 |
Abbreviations:IV, intravenous;PCI, percutaneous coronary intervention; PTCA, percutaneous coronary angioplasty; BMS, bare metal stent; DES, drug eluting stent; CABG, coronary bypass graft surgery; ACE, angiotensin converting enzyme
In hospital and one-year outcomes
|
|
|
|
|
| LVEF at discharge, median (Q1-Q3), % | 59 (50-61) | 55 (45-60) | 0.017 |
| Reinfarction, n (%) | 6 (3.4%) | 0(0.0%) | 0.592 |
| Cardiogenic shock, n (%) | 3 (1.7%) | 1 (2.8%) | 0.528 |
| Stroke, n (%) | 1 (0.6%) | 0 (0.0%) | 1.000 |
| Major bleeding, n (%) | 1 (0.6%) | 0 (0.0%) | 1.000 |
| Any bleeding, n (%) | 1 (0.6%) | 0 (0.0%) | 1.000 |
| Blood transfusion, n (%) | 0 (0.0%) | 0 (0.0%) | - |
| Mortality, n (%) | 2 (1.1%) | 1 (2.8%) | 0.429 |
| One year follow-up outcomes | |||
| Hospitalization, n (%) | 42 (23.9%) | 10 (27.8%) | 0.672 |
| Myocardial infarction, n (%) | 7 (4.0%) | 1 (2.8%) | 1.000 |
| Coronary angiography, n (%) | 28 (16.0%) | 4 (11.1%) | 0.612 |
| Cardiovascular death, n (%) | 2 (1.1%) | 1 (2.8%) | 0.429 |
| All-cause death, n (%) | 1 (0.6%) | 0 (0.0%) | 1.000 |
Abbreviations: LVEF, left ventricular ejection fraction